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Cancer cachexia is a frequent complication observed in patients with malignant tumors. Although several decades have passed
since the first focus on the metabolic dysfunction’s associated with cancer, few effective therapeutic interventions have been
successfully introduced into the medical armamentarium.
The present study thoroughly reviews the basic pathophysiology of cancer cachexia and the treatment options already investigated
in that field. Experimental and clinical studies were evaluated individually in order to clarify the intricate alterations observed in
tumor-bearing patients. The difficulties in introducing sound and effective nutritional support or metabolic manipulation to reverse
cancer cachexia are outlined in this review.
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The origin of malnutrition in can-
cer patients is multi-factorial. Anorexia
may be attributed to altered taste and
smell1, or to changes in the hypotha-
lamic food regulation2. Food intake is
diminished by mechanical obstruction
of the alimentary tract. Disturbance of
digestion and absorption also accom-
panies some tumors. Nutritional de-
mand in the tumor-bearing state is in-
creased due to alterations either by the
neoplasm itself or by the stressed host.
Wasting is accelerated by the proteoly-
sis of skeletal muscle and consumption
of body fat. Accelerated mobilization
and consumption of host protein stores
from peripheral tissues occurs to sup-
port gluconeogenesis and acute phase
protein synthesis3,4. In contrast, simple
starvation is associated with a relative
sparing of lean tissue with the prefer-
ential consumption of fat5,6. Substrate
consumption by the tumor, whether
based on analogy with glucose con-
sumption in the human brain7, on in
vivo studies in transplanted tumors8, or
on in vivo use of the substrate by sar-
coma-bearing human limbs9, can be
substantial and may account for small
increases in energy expenditure at rest.
However, only a very large tumor
(above 1.4 kg) would consume 50% of
the intake of the patient at rest10.
Understanding the basic mecha-
nisms of metabolic alterations ob-
served in the tumor-bearing state is the
basis for developing optimum treat-
ment for those patients with malig-
nancy.
In this chapter, the basic patho-
physiology of metabolic alterations
observed in the tumor-bearing state
both in animal and humans is pre-
sented, followed by a re-focusing on
clinical significance and current prob-
lems in applying nutritional support to
those patients.
I. Metabolic Alterations in Cancer
Patients
- Alterations specific to cancer patients-
1. Glucose Metabolism
Altered glucose metabolism in can-
cer patients is characterized by in-
creased whole-body glucose turnover
rate, decreased glucose uptake and uti-
lization due to insulin resistance, and
increased hepatic glucose synthesis, or
gluconeogenesis, from substrates de-
rived from proteolysis and lipolysis.
Whole-body carbohydrate metabolism
Increased whole-body glucose
turnover has been documented in gas-
trointestinal cancer patients, and this
increase was proportional to the extent
of the disease11. Whole-body glucose
production rates were also significantly
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increased in patients with lung cancer
(n=29, 3.4+0.2 mg/kg/min) compared
to levels in controls (n=18, 2.3+0.1 mg/
kg/min)12. In those patients, the fasting
serum alanine level was significantly
lower than for controls, suggesting that
alanine was being released at a normal
or enhanced rate and was utilized more
rapidly for the production of glucose in
patients than in controls. Increased
Cori cycle activity or glucose carbon
recycling in patients with malignant
disease is well documented by several
studies13,14,15.
Peripheral carbohydrate metabolism
Glucose intolerance is one of the
earliest recognized metabolic alter-
ations in patients with cancer. In ex-
perimental animal models, hypoglyce-
mia is a characteristic finding. In can-
cer patients, fasting hypoglycemia is
not commonly seen; however,
Glicksman and Rawson16 reported that
approximately 37% of all patients with
cancer had abnormal glucose tolerance.
Details of glucose intolerance or insu-
lin resistance are discussed in the fol-
lowing section. The decreased glucose
metabolized or glucose clearance from
the circulation resulted in both signifi-
cantly decreased glucose storage and
glucose oxidation in gastrointestinal
(GI) and lung cancer patients.
Increased circulating lactate was
found in animal models as well as in
some cancer patients. Studies in vivo
of human tumors demonstrated signifi-
cant glucose use and lactate produc-
tion17. Lactate thus produced may be
used by the liver as a gluconeogenic
precursor to synthesize glucose, which
may be used by both the host and the
tumor. In this process, energy is
wasted, because only 2 molecules of
ATP are produced by glycolysis while
6 molecules of ATP are utilized to syn-
thesize glucose from lactate.
Hepatic glucose metabolism
Increased gluconeogenesis in the
tumor-bearing state has been claimed
to be one of the major causes of can-
cer cachexia, mobilizing peripheral
lean tissue mass as a substrate for glu-
coneogenesis. Roh et al18 reported in-
creased gluconeogenesis from alanine
and lactate in tumor-influenced hepa-
tocytes in the presence of decreased
serum glucose level. It was associated
with increased gluconeogenic capacity
and accelerated alanine transport.
The increased energy cost of en-
hanced gluconeogenesis would only be
significant if this process persisted
throughout a 24-hour period and may
not be detected if feeding is a compen-
sating factor19. Waterhouse et al.20 dem-
onstrated normal suppression of in-
creased gluconeogenesis from alanine
with a small amount of carbohydrate in
overnight-fasted patients with progres-
sive malignant disease. This finding
brings into question the significance of
the observed increase in gluconeogen-
esis in the tumor-bearing state and em-
phasizes the possible regulation of this
catabolic pathway by nutritional ma-
nipulation21.
We previously studied the alter-
ations of this pathway by examining a
key regulatory enzyme, phospho-
enolpyruvate carboxykinase (PEPCK)
at both the activity and mRNA levels.
PEPCK is a well-studied pacemaker
enzyme of gluconeogenesis22. A num-
ber of hormones are known to regulate
the synthesis of this enzyme23, includ-
ing glucagon, epinephrine24, and thy-
roid hormone25, which increases, and
insulin, which decreases the synthesis.
PEPCK activity in liver cytosol, after
a 24-hour fast, was significantly higher
in tumor-bearing rats than in their pair-
fed controls. The increase in enzyme
activity was clearly evident at 8% tu-
mor burden and correlated positively
with the degree of tumor burden
(r=0.85, p<0.01). Removal of the tu-
mor produced a complete reversal of
PEPCK activity 10 days after excision.
Regular feeding also abolished this in-
creased enzyme activity. PEPCK
mRNA levels were equally elevated in
tumor bearers and controls in the 24-
hour-fasted state. These results suggest
that tumor-bearing stimulates the fasted
state associated with hypoglycemia,
which in turn triggers induction of the
gluconeogenic enzyme, PEPCK. Sub-
strate availability may be a key in in-
duction of gluconeogenesis in this tu-
mor animal model.
We also measured PEPCK activity
in the livers of GI cancer patients. Al-
though there were cases in which
PEPCK activity was elevated, the mean
value in patients with advanced GI can-
cer without significant weight loss was
not different from that of controls (sub-
mitted for publication). Increased glu-
coneogenesis in cancer patients has
been documented by isotope infusion
techniques, but no data on PEPCK ac-
tivity in the liver is available except our
current study. If this enzyme is a key,
therapy targeting this enzyme may
modulate cancer cachexia. Hydrazine
sulfate inhibits the conversion of oxalo-
acetate to phosphoenolpyruvate by in-
hibiting PEPCK irreversibly, and 3-
mercaptopicolinic acid is a specific
blocker of PEPCK. Although clinical
trials had been attempted on both
drugs, no significant benefits were
demonstrated26,27,28.
2. Fat Metabolism
Fat loss is frequently observed in
advanced malignant disease, but may
also occur in patients with early stage
cancer when tumor volume is still rela-
tively small29. Studies in experimental
animals have shown a progressive
depletion of carcass fat stores during
tumor growth30,31,32. Profound alter-
ations in host lipid metabolism occur
in both tumor-bearing animals33,34,35,36
and humans37,38,35,15,39,40, manifested by
hypertriglyceridemia and increased cir-
culating non-esterified fatty acid
(NEFA).
183
REV. HOSP. CLÍN. FAC. MED. S. PAULO 55(5):181-193, 2000SEPTEMBER-OCTOBER
Hyperlipidemia and whole-body lipid
kinetic study
In our model of Fisher 344 rats
with methylcholanthrene-induced
(MCA) sarcoma, hyperlipidemia is one
of the early changes, progressively
aggravated by tumor growth and com-
pletely abolished by curative tumor re-
moval. In human cancers, some pa-
tients with leukemia and lung cancers
have been documented to have elevated
levels; however, hyperlipidemia is not
universally observed41. Patients with
solid tumors such as esophageal, gas-
tric, colorectal, and breast cancer very
rarely manifest these alterations42.
Shaw and Wolfe43 demonstrated in-
creased rates of glycerol and fatty acid
turnover in weight-losing gastrointes-
tinal cancer patients, compared with
either weight-stable cancer patients or
controls.
De novo fatty acid synthesis
We have previously shown that de
novo fatty acid biosynthesis in the liv-
ers of tumor-bearing rats is signifi-
cantly decreased as a function of de-
gree of tumor burden33. Lipogenesis by
adipose tissue was also shown to be
decreased in the tumor-bearing
mouse44. Thompson et al.44 demon-
strated a gradual decline of lipogenesis
per gram wet weight of liver with tu-
mor growth by measuring the incorpo-
ration of 3H from 3H2O into lipids.
Their conclusion was that the total
amount of lipid synthesis was not sig-
nificantly altered in tumor-bearing
mice, since liver weight increased as
the tumor grew. However, the tissue
composition analysis of our model45
has previously shown that liver protein
content in tumor-bearing animals is no
greater than that of pair-fed controls,
although liver wet weight of the former
is greater than that of the latter.
Beta oxidation
 Arbeit46 and Hansell47 in separate
studies documented that patients with
diffuse disease or weight loss had sig-
nificantly higher fat oxidation rates,
while Waterhouse et al48 could not see
a significant difference in the rate of
NEFA oxidation under basal conditions
in cancer patients and control. We ex-
amined the role of fatty acid oxidation
by carnitine palmitoyltransferase activ-
ity in the Fisher344 rat with MCA sar-
coma49. This enzyme is bound to both
the inner and outer surface of the inner
mitochondrial membrane and regulates
the membrane transport of cytosolic
fatty acylCoA into mitochondrial matrix
where oxidation takes place50. In this
model, there was no difference in en-
zyme activity between tumor-bearing
rats and controls, which suggested that
the tumor bearers did not utilize an aug-
mented supply of NEFA for oxidation
in the fed state. Since fatty acylCoA
formed in the cytosol is either oxidized
in the mitochondria or converted to TG
and phospholipids in the cytosol, en-
hancement of the latter may contribute
to the significant increase in circulating
TG levels.
Lipolysis
The rate of free fatty acid (FFA)
production in epididymal adipose tis-
sue removed from tumor-bearing rats
was shown to be increased, compared
to that of controls51. We previously
documented on increased rate of li-
polysis (elevated FFA-Ra), associated
with the maintained FFA clearance rate
by the hepatocytes, which are major
sites of uptake of FFA in Fisher344 rats
with MCA sarcoma52. A significant in-
crease in the FFA-Ra has been also
shown in patients with significant
weight loss53.
Why is liberation of FFA needed in
the tumor-bearing state? Some inves-
tigators have suggested that tumor
growth is associated with an enhanced
mobilization of stored triglycerols so
that the resulting liberation of FFA can
be utilized for tumor growth54. How-
ever, the delivery rate of FFA to rap-
idly growing tumors is slow39. An aug-
mented supply of NEFA by lipolysis to
the liver44,55 may not be utilized for oxi-
dation56 preferentially esterified to
form TG, which is secreted as very low
density lipoprotein.
Lpolytic factor
The concept of a lipolytic factor se-
creted by the tumor has been pro-
posed57,58. Costa and Holland32 were
able to induce a substantial fat loss in
non-tumor-bearing mice following the
injection of nonviable tumor prepara-
tion. Although data from several stud-
ies indirectly support the existence of
a tumor-related “lipolytic factor”, at-
tempts to discover such a factor have
been unsatisfactory in animal models41
and patients40,51.
Triglyceride clearance
Lipoprotein lipase (LPL), synthe-
sized by parenchymal cells of adipose
and muscle tissues and transported to
the vascular endothelium, regulates the
rate at which hydrolysis of circulating
TG occurs, delivering NEFA for meta-
bolic needs of the tissue59. This enzyme
is unique in that the tissue-specific
changes in the catalytic activity closely
reflect alterations in the physiological
state. Reciprocal changes during star-
vation in LPL activity in muscle, where
LPL provides fatty acids for fuel, and
adipose tissue, where the acyl groups
are used for TG storage, are well docu-
mented60,61.
We documented decreased enzyme
activity with increasing tumor burden,
and the reversal of these changes, by
tumor removal in Fisher344 rats with
MCA sarcoma62. One possible mecha-
nism to explain the decreased LPL in
the fasted tumor-bearing rats is hy-
poglycemia, induced by the presence
of tumor. The LPL response to dietary
carbohydrate appears to depend largely
on the insulin secretory response to the
ingested carbohydrate63. The finding
that withdrawal of glucose from the
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media decreased LPL activity in 3T3-
L1 adipocytes56 suggests that the sub-
strate itself may play an important role
in the regulation of this enzyme. Ong
and Kern64 demonstrated that insulin
stimulated LPL by increasing the level
of LPL mRNA, whereas glucose
stimulates LPL translation and post-
translational processing in cultured rat
adipocytes.
Our results in adipose tissue agree
with those of Thompson et al44 and
Lanza-Jacoby 65. Vlassam et al66 docu-
mented a reduction in post-heparin
plasma LPL activity in overnight fasted
patients with malignant-associated
weight loss. The level of total periph-
eral LPL correlated well with the pres-
ence of body weight loss in their pa-
tients (r=0.6, p<0.01). Our recent data
on post-heparin serum LPL in GI and
breast cancer patients revealed that de-
creased LPL activity in those patients
was significantly correlated with de-
gree of weight loss and with advanced
stages of disease. However, complete
tumor removal did not result in rever-
sal of deceased LPL activity, unlike in-
sulin resistance in glucose metabo-
lism67. Decreased LPL activity in the
absence of hyperlipidemia, especially
in patients with GI or breast cancer,
may be induced by malnutrition, not by
tumor effects. Therefore, in studying
lipid metabolism in cancer patients,
classification of subsets of patients into
those with and without hyperlipidemia
may be the key in further dissecting the
mechanisms of these alterations.
3. Protein Metabolism
Tumors have been known not only
as “glucose eaters” but also as “nitro-
gen sinks”, depleting the host of pro-
tein mass and resulting in characteris-
tic alterations in protein metabolism.
Several investigators have suggested
that redistribution or translocation of
peripheral proteins to support visceral
or tumor protein synthesis is an essen-
tial feature of amino acid metabolism
in cancer cachexia68. Because the rate
of protein synthesis in human tumors
is approximately the same as that of the
tissue of origin69, and human tumors
rarely exceed 1% of body mass70, the
observed alterations in whole-body
protein metabolism are unlikely to be
secondary to the tumor itself, but rather
to tumor-influenced alterations in host
protein metabolism71.
Aminograms
Basal postabsorptive aminograms in
several homogeneous groups of patients
with different malignancies have been
reported with variable results. Only one
paper by Clarke et al.72 showed elevations
of alanine, isoleucine, and lysine, but all
the others showed either decrease or no
alterations. Heber et al.12 demonstrated
decreased alanine levels in patients with
advanced lung cancer. Those may sup-
port the hypothesis that gluconeogenesis
from alanine and other gluconeogenic
precursor proteins is increased. In 55 pa-
tients with a variety of tumors, proline
levels were significantly reduced in lym-
phoma and sarcoma patients. Patients
with esophageal cancer and weight loss
demonstrated a marked reduction in all
circulating amino acids except BCAA.
No cancer-specific amino acid profile has
emerged from the studies so far pub-
lished73,74. However, it appears that pa-
tients with extraintestinal nonobstructive
malignancies have minimal aberrations
in their amino acid profiles, and it is pos-
sible that with more advanced malig-
nancy with weight loss, more profound
changes in amino acid concentrations
occur.
Whole-body protein metabolism
With few exceptions, whole-body
protein turnover, synthesis, and catabo-
lism have been reported to be elevated
in both tumor-bearing animals75 and
cancer patients. Those changes are not
tumor-site specific but may be related to
the advancement of the tumor. Shaw et
al43 examined rates of whole-body pro-
tein synthesis and catabolism by isoto-
pic infusion of alpha-[15N]-lysine and
[15N]2-urea in 20 patients with ad-
vanced-weight-loss (AWL) upper gas-
trointestinal cancer, 7 patients with early
non-weight-loss (ENWL) lower gas-
trointestinal cancer, and a group of vol-
unteers. ENWL cancer patients and nor-
mal volunteers had similar protein dy-
namics, and in both groups, glucose in-
fusion resulted in a significant decrease
in protein loss. In AWL cancer patients,
the rate of net protein catabolism was
significantly higher than in either the
volunteer or ENWL group (p<0.05).
Glucose infusion did not result in a de-
crease in net protein catabolism. TPN
significantly decreased net protein ca-
tabolism from 2.24+0.30 to 0.17+0.09
gm/kg/day (p<0.01). This decrease was
due to the combined effect of a signifi-
cant decrease in whole-body protein ca-
tabolism coupled with an increase in
whole-body protein synthesis. Increase
in whole-body protein catabolism—and
whole-body protein synthesis to a lesser
extent—in patients with cancer cachexia
from a variety of tumors (n=47) was
also confirmed in the subsequent study
by the same group by intraoperative iso-
topic infusion of 14C-leucine83. They
concluded that patients with cancer
cachexia were actively losing protein as
a result of an increase in whole-body
protein catabolism that was only par-
tially compensated for by an increase in
whole-body protein synthesis. In a pa-
tient group studied by Borzotta et al.79,
patients with advanced malignancy or
stage 4 cancer had significantly greater
protein turnover, synthesis, and catabo-
lism than patients with localized disease.
Similarly, significant correlation be-
tween alterations in protein metabolism
and stages of disease was documented
by Carmichael et al.68.
Skeletal muscle protein metabolism
and regional amino acid kinetic study
A common effect of tumor-bearing
on protein metabolism in skeletal
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muscle has been shown to be depressed
protein synthesis and increased protein
breakdown. Clark et al.90, demonstrated
those changes in the skeletal muscle in
rats bearing the Wealker 256 carci-
noma. Gastrocnemius muscle weight,
RNA/DNA ratio, and incorporation of
14C-valine were significantly decreased.
Incorporation of 3H-lysine into protein
in the gastrocnemius polysome prepa-
ration was decreased, and net tyrosine
release and 14CO2 production from 14C-
leucine, representing protein degrada-
tion, were increased.
Lundholm et al.85,77 examined the
regional amino acid kinetics in rectus
abdominus muscle obtained at surgery
from 43 cancer patients with a variety
of tumors and 55 controls. They dem-
onstrated a significant decrease in the
in vitro incorporation of 14C-leucine
into skeletal muscle protein and an in-
crease in the fractional degradation rate
of proteins in cancer group compared
with control. Emery et al.77 confirmed
the significantly decreased protein syn-
thesis in 5 cancer patients with weight
loss by 13C-leucine enrichment in quad-
riceps protein obtained by percutane-
ous biopsy. Protein synthesis in muscle
was 0.030%/hour in cancer patients
and 0.198 in controls (p<0.01). Al-
though most claimed decreased protein
synthesis rates in the muscle, only one
group found the fractional synthetic
rate of protein in rectus abdominus
muscle to be increased in cancer pa-
tients with cancer cachexia83.
Contrary results were also reported.
Newman et al.91, evaluated forearm
phenylalanine exchange kinetics by in-
fusion of L-phenylalanine under
baseline and postabsorptive conditions
in 16 cancer patients and 12 healthy
controls and found no significant dif-
ference in phenylalanine kinetics in the
basal state. Indirect evaluation of skel-
etal muscle protein catabolism by 3-
methylhistidine documented no in-
crease in cancer patients92. Whether
those differences derive from differ-
ences in methodology or different
types of tumor or stages is not clear.
Hepatic protein metabolism
Generally, protein synthesis in the
liver has been reported to be increased
in the tumor-bearing state. In the MCA
101 tumor-bearing mouse, increased
incorporation of leucine in liver tissue
was documented by Lundholm et al.93.
They suggested that the tumor-bearing
state was associated with an increased
translational capacity.. Several systems
have been defined as mechanisms of
amino acid transport in liver. In the
Fisher344 rat with MCA sarcoma, both
System N (glutamine) and System y+
(arginine) were increased in the pres-
ence of the tumor, while System A
(MeAIB) was unaltered. The observa-
tion that hepatic glutamine transport
activity remained augmented after tu-
mor resection longer than any other
transport systems studied suggested a
key role for this amino acid in overall
hepatic nitrogen metabolism and might
partially explain the persistent
glutamine depletion that was character-
istic of the tumor-bearing host94. The
arginine pathway, which plays a pivotal
role in regulating ureagenesis,
polyamine biosynthesis, and nitric ox-
ide production, was significantly stimu-
lated in liver of the tumor-bearing
Fisher 344 rats. This response was me-
diated by an increase in activity of Sys-
tem y+95.
In human studies, an increased in
vitro incorporation of 14C-leucine into
homogenized hepatic proteins of can-
cer patients compared with normal
controls was demonstrated85. Increased
fractional synthesis rates (FSR) of pro-
tein in liver (p<0.05) and of albumin
(p<0.01) have been confirmed in vivo
in cancer cachexia patients compared
with either non-weight losing cancer
patient or normal control83. Patients
with NWLC had a mean FSR of pro-
tein in liver of 18.3%+2.2% per day. In
contrast, the corresponding value in the
patients with cancer cachexia was
29.7%+5.0% per day.
4. Energy Metabolism
Studies on energy metabolism dur-
ing prolonged fasting are a sharp con-
trast to the condition of cancer—de-
creased energy expenditure with in-
creasing starvation. In the cancer, the
propensity for elevated energy expen-
diture in the face of reduced intake has
been attributed to a maladaptation of
the host to the starvation state4. Al-
though there is general agreement that
cancer patients experience elevated en-
ergy expenditures, several studies have
been reported with varied results.
Some investigators have attempted
to overcome the problems of the Har-
ris-Benedict formula by normalizing
the REE to the metabolically active tis-
sue (body cell mass)46. In noncachectic
sarcoma patients (n=7), there was a
significantly lower percentage of BCM
than in controls. Reflecting this, the
REE corrected for BSA was 25%
greater in male sarcoma patients than
in male controls (p<0.05), and this dif-
ference was doubled when REE was
corrected for BCM (p<0.01). They
concluded that both REE and vital,
functional BCM could be significantly
altered in sarcoma patients before any
overt signs of cachexia develop99.
Hansell et al.47 assessed the hypoth-
esis that different tumor types exert dif-
ferent effects on REE. REE in 84 can-
cer patients correlated significantly
with body weight and lean tissue mass.
The slope of the regression line for the
bronchial cancer patients was signifi-
cantly different from the colorectal and
gastric cancer patients when REE was
related to LBM. When REE in the
same organ was compared, and results
differed. In gastric cancer patients,
Frederic et al96 could not demonstrate
any elevation, while Dempsey et al.98
found significant elevation.
There is no widespread agreement
concerning alterations in energy me-
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tabolism in cancer patients. The use of
a heterogeneous cancer group may be
inappropriate in studies of REE as in
other parameters in cancer. When REE
is significantly elevated there is more
likelihood for the disease to be widely
spread.
5. Mediators—cytokines
Recently, there has been much in-
terest in a variety of monokines, be-
cause they can elicit a metabolic re-
sponse very similar to that seen in the
cachectic syndrome induced by tu-
mors: loss of appetite, loss of body
weight (body fat and protein), and in-
duction of acute phase protein synthe-
sis100. These similarities alone do not
prove a cause-and-effect relationship.
Possible transfer of endogenous media-
tors via the circulation was demon-
strated by the development of cachexia
in non-tumor-bearing rats after parabi-
otic anastomosis to sarcoma-bearing
cachectic rats 101). However, the results
reported by different investigators are
not always the same.
TNF-alpha
TNF-alpha/cachectin, a 17kDa pro-
tein consisting of 157 amino acids, is
produced by stimulated reticuloendot-
helial cells, principally macrophages
and monocytes102. The receptors for
TNF have been identified in nearly all
tissues103. The half-life is 14-18 min in
humans and 10 min in mice104. TNF is
a well-documented growth factor for
many normal cells, stimulating cellu-
lar growth and differentiation105, and
inducing production of a variety of
compounds, including PGE2, collage-
nase, platelet activating factor, IL-1 and
IL-6106. TNF also enhances angiogen-
esis107.
A single injection of TNF alpha can
cause a characteristic weight loss due to
a reduction in food and water intake and
a decreased carcass water content108.
However, when rats received chronic (5-
day) infusions of rH-TNF, profound an-
orexia and fluid retention, but not accel-
erated nitrogen losses, were observed109.
Darling and Norton110 reported that a
continuous i.v. infusion of TNF, rather
than an intermittent bolus i.v. resulted in
a decreased food intake and a decreased
nitrogen balance. After 4 days of treat-
ment, rats treated with intermittent bo-
lus doses of TNF developed tolerance.
The TNF decreases LPL activity and in-
creases hepatic lipogenesis111,112. Cells
transfected with the TNF gene inserted
near an active promotor were injected
into nude mice, which produced a sus-
tained release of TNF and resulted in a
severe wasting of host body fat and lean
tissue mass, progressive cachexia and
eventual death113,114,115. Active TNF
genes were demonstrated in the tumor
and lymphoid tissue of MCA sarcoma-
bearing mice116 and in human colorectal
tumors117. However, only a few papers
have documented increased serum TNF
in tumor-bearing patients118,119. No cor-
relation between severity of cachexia
and TNF concentrations was found120,121.
IL-6
IL-6, a 26kDa protein, is perhaps
the most extreme example of a pleio-
tropic cytokine. It has a broad range of
activities on different cells and was
originally found as a growth factor for
transformed B-cells122. Some of its
functions include stimulation and dif-
ferentiation of B-cells (BSF-2)123, sup-
porting hybridoma and plasmacytoma
cell growth (HGF/PGF), and stimulat-
ing synthesis of host response proteins
by liver following exposure to toxic
materials or injury (HSF) 124. IL-6 is
secreted by monocytes, fibroblasts,
keratinocytes, endothelial cells,and B-
cells. A specific, high affinity receptor
for IL-6 is distributed on many differ-
ent cells throughout the organism.
Is IL-6 the circulating message that
induces anorexia125 and the hepatic
acute phase reactants? Elevated serum
levels of IL-6 were demonstrated in
Balb/c x DBA/2(CD) mice with colon
26 carcinoma126. The effects of IL-6 in
vivo were assessed by inoculating nude
mice with Chinese hamster ovarian
cells that had been transfected with the
murine IL-6. Only those inoculated
with the transfected IL-6 gene demon-
strated a number of paraneoplastic syn-
dromes including hypercalcemia,
cachexia, leukocytosis, and thrombocy-
tosis127. Both the injection of IL-6 in
mice and the culture of 3T3-L1
adipocytes in the presence of IL-6 re-
duced tissue and heparin-releasable
LPL activity in a dose-dependent man-
ner128. IL-6 was also demonstrated
immunohistochemically in human tu-
mor specimens129. Furthermore, some
of the alterations were reversed by neu-
tralizing antibodies to IL-6 (eg. the hy-
percalcemia associated with a human
squamous cell carcinoma130, the deple-
tion of carcass weight and epididymal
fat, hypoglycemia, and the increase in
serum amyloid P126).
Why are cytokines not found in the cir-
culation ?
To determine a cause and effect re-
lationship between a molecule and any
putative effects it may have in vivo, the
molecule must first be demonstrated to
be in the circulation at the time when
host response is initiated125.
Although Stovroff et al. demon-
strated that TNF in the circulation of
cachectic sarcoma-bearing rats was
correlated with tumor burden and dis-
appeared following tumor resection114,
and Balkwill et al detected labile TNF
activity by means of an enzyme-linked
immunosorbent assay in 50% of 226
freshly obtained serum samples from
cancer patients with active disease 118,
increased circulating TNF concentra-
tions are not a regular finding in human
or experimental cancer disease116,132,121.
The magnitude of weight loss and the
appearance of TNF in the circulation
seem to be poorly correlated133. Ana-
lytical results at a molecular level are
also controversial. Northern blot analy-
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sis of human colorectal cancer speci-
mens showed the presence of mRNA
for TNF in 15 of 28 tumor samples and
6 of 26 matched normal tissue samples.
TNF localized by in situ hybridization
was demonstrated to correlate to acti-
vated macrophages that infiltrated the
tissue. No one had detectable IL-1 or
IL-6 mRNA in tumor or normal tis-
sues, although all tissues tested ex-
pressed TGF-1134. Up-regulation of
TNF gene transcription was also found
in the liver and spleen despite an in-
ability to detect circulating cachectin116.
 Many factors have been used to ex-
plain the low circulating levels of some
of the cytokines. However, the difficulty
in detecting TNF in the plasma of can-
cer patients and the ease of detecting it
in cases of sepsis and severe infection
does not lead us to conclude that the
same molecule works differently in dif-
ferent disease state (i.e. as an autocrine
or paracrine factor in cancer and as an
endocrine factor in infection). No other
hormones function through different
mechanisms, depending on the patho-
logic conditions, unless other factors
can recognize the different pathologies.
There are increasing data that suggest a
role for cytokines in mediating cancer
cachexia. However, other reports argue
against it. Whether cytokines and a
cytokine network are responsible for in-
ducing cancer-specific metabolic alter-
ations or not has to be clarified in fur-
ther study.
6. Insulin Resistance in Cancer
Insulin resistance in the tumor-
bearing state was found as early as
1919 by Rohdenberg et al.135.
Lundholm et al.136 showed that a de-
crease in glucose after insulin infusion
is quantitatively smaller in cancer pa-
tients compared with controls. Insulin
resistance is generally defined as quan-
titative decrease in response to insulin
infusion137. It is not rare to find an ab-
normal glucose tolerance in cancer pa-
tients. Glicksman et al.138, examining
600 cancer patients by glucose toler-
ance tests, found that 37% of those ex-
amined demonstrated a diabetic pat-
tern. In contrast with other alterations,
more data on insulin resistance has
come from human studies. Initially, it
was considered that insulin resistance
was the result of malnutrition; however,
insulin resistance was found even in
those with early sarcoma, esophageal
cancer139, and non-oat cell carcinoma.
Insulin resistance in glucose metabo-
lism
Lundholm et al.144 documented that
in malnourished cancer patients, both
insulin sensitivity and responsiveness
were decreased in 50%, 70-80% of in-
fused glucose during glucose clamp
was taken up by the peripheral tissue,
and insulin sensitivity in the peripheral
tissue was lower than that in the whole
body sensitivity. The decreased insulin
sensitivity in the peripheral tissue was
difficult to reverse with a large amount
of insulin.
Copeland et al.143, examining 12 pa-
tients with colorectal cancer, docu-
mented that responsiveness (maximal
glucose disposal) was decreased com-
pared to controls, but sensitivity (insu-
lin concentration of half maximal glu-
cose disposal) was not different. These
findings suggest that insulin resistance
occurs as a post-receptor defect. Most
data so far reported agree that glucose
disposal is decreased in many cancer
patients. The only contradictory paper
came from Byerley on patients with
head and neck tumors140. In their study,
glucose disposal rate was increased in
cancer patients, suggesting an increased
drainage of glucose into the tumor.
However, insulin clearance rate was in-
creased in their patients, which might
result in increased glucose disposal.
We examined insulin sensitivity in
both weight-losing and weight-stable
patients with cancer and compared
their results with those of a normal vol-
unteer. There was significant decrease
in glucose metabolized and metabolic
clearance of glucose in both the
weight-stable and weight-losing pa-
tients compared with controls. This de-
crease was reversed by complete tumor
removal, suggesting that insulin resis-
tance in patients with cancer is not a
result of cancer-associated malnutrition
but is related to the tumor itself67.
Insulin resistance in lipid metabolism
There have not been many papers on
this issue. The presence of insulin resis-
tance in LPL activity was documented
in studies in vivo and in vitro with MCA
sarcoma-bearing rats146. McRussel et
al.145 found that hyperlipidemia (FFA,
80+62uM) observed in patients with
small cell lung cancer under chemo-
therapy with hyperalimentation did not
respond to the high insulin level of
5.07+1.66 ng/ml and suggested the
presence of insulin resistance in those
patients. In our study during glucose
clamp, changes in TG, FFA, very low
density lipoprotein (VLDL), and LDL
levels were not related with M values
calculated from the insulin clamp tech-
nique. In septic cancer patients, insulin
resistance in FFA turnover was more
apparent than resistance in suppressing
endogenous insulin production. The
antilipolytic effect of insulin is induced
by 1/4 of the amount necessary for glu-
cose utilization and ½ of that required
for suppressing endogenous glucose
production. Therefore, insulin resistance
in lipid metabolism may be more diffi-
cult to be demonstrated147.
Insulin resistance in protein metabo-
lism
The influence of insulin on protein
synthesis from phenylalanine in the
C57BL/6J mouse skeletal muscle and
from leucine in the rectal muscle of
cancer patients revealed no difference
between cancer patients and controls148.
Amino acid alterations during
hyperinsulinemic glucose clamp were
not related with glucose metabolized or
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M values (unpublished data). Insulin
action on arterial BCAA concentra-
tions and forearm BCAA flux was in-
vestigated in 6 weight-losing patients
with localized gastrointestinal cancer
by euglycemic hyperinsulinemic
clamp. Progressive euglycemic insulin
infusion induced a marked, compa-
rable insulin-dependent decrease in ar-
terial plasma BCAA concentrations in
both patients and controls. There was
no difference in post-absorptive fore-
arm BCAA flux with progressive
hyperinsulinemia. Insulin-induced
branched-chain hypoamino acidemia
was unimpaired in this group of pa-
tients. Those provide evidences of dif-
ferential resistance to insulin action in
glucose and protein metabolism 74.
Mechanisms of insulin resistance in
cancer
Mechanisms of insulin resistance in
cancer patients have not yet been clari-
fied. Therefore, mechanisms in diabe-
tes mellitus referred to here and theo-
retical mechanisms are summarized in
table 1. The increase in catabolic hor-
mones in cancer patients such as glu-
cagon, cortisol, and catecholamine is
one possibility147. Ojamaa et al.149 sug-
gested a decrease in insulin receptor
mRNA and synthesis rate of insulin re-
ceptors, a defect at the post-transla-
tional levels, or decreased translocation
of the transport proteins to the plasma
membrane in diabetic patients. Haring
et al.150, studying the Claudman S91
melanoma cell, documented decreased
affinity of receptors to insulin and de-
creased autophosphorylation of beta-
subunit tyrosine kinase. Significant
correlation between decreased activa-
tion of tyrosine specific protein kinase
(beta-subunit) and insulin resistance
has been suggested. From the fact that
the number of insulin receptors neces-
sary for insulin to induce its effect is
less than 5% of total insulin receptors,
Krett et al.151 suggested the greater im-
portance of post-receptor events as
compared to number of insulin-binding
sites.
The mechanisms of defects in ki-
nase is complex, including 1) defects
in autophosphorylation of receptor ki-
nase, 2) an alteration in ATP-binding
sites for insulin receptor tyrosine ki-
nase, resulting in decreased activity of
insulin receptor tyrosine kinase, 3)
presence of insulin insensitivity. Other
possible mechanisms may include a
defect in internalization of insulin re-
ceptors, decreased intracellular uptake
of insulin-receptor complex, and a de-
fect in signal transduction between re-
ceptor kinase and glucose transporter.
Dissection of the mechanisms of insu-
lin resistance may give us another key
to solve the complex mechanisms of
cancer cachexia.
CONCLUSIONS
Tumor-bearing hosts suffer from
tumor-induced metabolic alterations,
some of which are secondary to mal-
nutrition and others that are tumor-spe-
cific changes. In evaluating those alter-
ations, the type of the tumor and the
stages of the cancer may have to be
taken into account.
As in other data, animal results may
not necessarily be applicable to tumor-
bearing humans. Nutritional support
can reverse most but not all alterations.
Indications of nutritional support have
to be determined from patient-benefit
considerations as well as tumor growth.
The selection of patients for intensive
nutritional support should be recog-
nized as a science not an art. To this
end, further dissection of basic mecha-
nisms of tumor-induced metabolic al-
terations is necessary.
Table 1 - Mechanisms of insulin resistance.
1. Abnormal insulin molecule
2. A defect in conversion from proinsulin to insulin
3. Increased counter regulatory hormones
4. Anti-insulin antibody
5. Abnormalities at the level of receptor
a) ecreased number of receptor or affinity
b) anti-insulin receptor antibody
c) a defect in translocation of the receptor
d) decreased activity of tyrosine specific protein kinase
e) a defect in internalization of insulin receptor
6. A defect at the post-receptor level
a) glucose transporter
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RESUMO RHCFAP/3022
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181-193, 2000.
A caquexia é uma complicação
freqüentemente observada em pacien-
tes portadores de tumores malignos.
Apesar de várias décadas transcorre-
rem desde a descrição inicial das
disfunções metabólicas associadas ao
câncer, poucas medidas terapêuticas
foram induzidas com sucesso na práti-
ca médica.
O presente estudo apresenta uma re-
visão detalhada da fisiopatologia bási-
ca da caquexia em câncer, e as opções
terapêuticas desenvolvidas nesta área.
Estudos experimentais, assim como clí-
nicos, são avaliados individualmente
para esclarecer as alterações complexas
observadas em pacientes portadores de
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